Suppression of the allogeneic response by the anti-allergy drug N-(3,4-dimethoxycinnamonyl) anthranilic acid results from T-cell cycle arrest

Immunology

Volumn 138, Issue 2, 2013, Pages 157-164

  Zaher, Sarah S ^a,b   Coe, David ^a   Chai, Jian Guo ^a   Larkin, Daniel F P ^a,b   George, Andrew J T ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Cell cycle; Rodent; Transplantation

Indexed keywords

INTERLEUKIN 2; PROTEIN P15; PROTEIN P21; TRANILAST; TRYPTOPHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CLONAL ANERGY; CONTROLLED STUDY; CORNEA TRANSPLANTATION; CYTOKINE PRODUCTION; GRAFT REJECTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN GRAFT; SURVIVAL; T LYMPHOCYTE;

ANIMALS; ANTI-ALLERGIC AGENTS; CELL CYCLE CHECKPOINTS; CELL DEATH; CLONAL ANERGY; CORNEAL TRANSPLANTATION; GRAFT REJECTION; GRAFT SURVIVAL; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; ORTHO-AMINOBENZOATES; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TRYPTOPHAN;

EID: 84872554474     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12026     Document Type: Article

References (26)

1. Ogawa Y, Dogru M, Uchino M et al. Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD. Bone Marrow Transplant 2010; 45:565-9.
2. Azuma H, Banno K, Yoshimura T. Pharmacological properties of N-(3′, 4′-dimethoxycinnamoyl) anthranilic acid (N-5′), a new anti-atopic agent. Br J Pharmacol 1976; 58:483-8.
3. Komatsu H, Kojima M, Tsutsumi N, Hamano S, Kusama H, Ujiie A, Ikeda S, Nakazawa M. Mechanism of inhibitory action of tranilast on the release of slow reacting substance of anaphylaxis (SRS-A) in vitro: effect of tranilast on the release of arachidonic acid and its metabolites. Jpn J Pharmacol 1988; 46:53-60.
4. Komatsu H, Kojima M, Tsutsumi N, Hamano S, Kusama H, Ujiie A, Ikeda S, Nakazawa M. Study of the mechanism of inhibitory action of tranilast on chemical mediator release. Jpn J Pharmacol 1988; 46:43-51.
5. Tanaka K, Honda M, Kuramochi T, Morioka S. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis 1994; 107:179-85.
6. Miyazawa K, Hamano S, Ujiie A. Antiproliferative and c-myc mRNA suppressive effect of tranilast on newborn human vascular smooth muscle cells in culture. Br J Pharmacol 1996; 118:915-22.
7. Nie L, Mogami H, Kanzaki M, Shibata H, Kojima I. Blockade of DNA synthesis induced by platelet-derived growth factor by tranilast, an inhibitor of calcium entry, in vascular smooth muscle cells. Mol Pharmacol 1996; 50:763-9.
8. Izawa A, Suzuki J, Takahashi W, Amano J, Isobe M. Tranilast inhibits cardiac allograft vasculopathy in association with p21(Waf1/Cip1) expression on neointimal cells in murine cardiac transplantation model. Arterioscler Thromb Vasc Biol 2001; 21:1172-8.
9. Spiecker M, Lorenz I, Marx N, Darius H. Tranilast inhibits cytokine-induced nuclear factor κB activation in vascular endothelial cells. Mol Pharmacol 2002; 62:856-63.
10. Platten M, Ho PP, Youssef S et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005; 310:850-5.
11. Inglis JJ, Criado G, Andrews M, Feldmann M, Williams RO, Selley ML. The anti-allergic drug, N-(3′, 4′-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis. Rheumatology (Oxford) 2007; 46:1428-32.
12. King WJ, Comer RM, Hudde T, Larkin DF, George AJ. Cytokine and chemokine expression kinetics after corneal transplantation. Transplantation 2000; 70:1225-33.
13. Beutelspacher SC, Pillai R, Watson MP, Tan PH, Tsang J, McClure MO, George AJ, Larkin DF. Function of indoleamine 2, 3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 2006; 36:690-700.
14. + T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival. Invest Ophthalmol Vis Sci 2011; 52:2640-8.
15. Ardjomand N, McAlister JC, Rogers NJ, Tan PH, George AJ, Larkin DF. Modulation of costimulation by CD28 and CD154 alters the kinetics and cellular characteristics of corneal allograft rejection. Invest Ophthalmol Vis Sci 2003; 44:3899-905.
16. + T cells and self-antigen-presenting cells. Invest Ophthalmol Vis Sci 2001; 42:2878-84.
17. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366:701-4.
18. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75:805-16.
19. Ward MR, Sasahara T, Agrotis A, Dilley RJ, Jennings GL, Bobik A. Inhibitory effects of tranilast on expression of transforming growth factor-β isoforms and receptors in injured arteries. Atherosclerosis 1998; 137:267-75.
20. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9:1149-63.
21. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995; 6:387-400.
22. Lorens JB, Bennett MK, Pearsall DM et al. Retroviral delivery of peptide modulators of cellular functions. Mol Ther 2000; 1(5 Pt 1):438-47.
23. + T-cell anergy selectively associates with mitogen-activated protein kinases. Immunology 2010; 129:589-99.
24. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010; 185:3190-8.
25. Prud'homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V, Jothy S. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS ONE 2010; 5:e13831.
26. + cells. J Transl Med 2011; 9(Suppl. 2):P27.